How do you approach the management of patients with one clinical demyelinating event and MOG+ antibody status?   

I do not always treat a MOG+ single event (isolated optic neuritis, isolated transverse myelitis, or ADEM-like presentation) as it is possible that it might be a one-time-only event (as might occur after a viral illness or vaccination). If there has been "dissemination in time", then I would consid...

As Dr. @Jagannadha Avasarala and Dr. @Robert Shin described, this is a great but tough question. As we know, all patients with MOGAD do not have a relapsing disease course, but I think it is also important to consider that the relapsing course of MOGAD can be very different than other demyelinating ...

I typically treat this group of patients. The antibody titer levels are perhaps important to correlate with disease phenotype but because antibodies fluctuate, it is almost impossible to predict if the patient will have another demyelinating event and have a catastrophic event. Since MOGAD has no FD...